GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
GSK has entered into an agreement with Novartis to take complete control of their joint venture, known as Consumer Healthcare. As of now, the seller (Novartis) has a 36.5 per cent stake in the joint venture. GSK is set to buy the stake for a total of $13 billion, following which the UK-based acquirer will be able to reap the full fruits of the JV's future performance. The Consumer Healthcare Joint Venture, which is being sold, was formed between GSK and Novartis on approval of shareholders in 2014. (Also Read: GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion)
As GSK is set to buy Novartis stake in consumer healthcare, here are eight things to know:
3. The buyout is also conditional to the government's green signal to the deal. It is expected that there is no governmental orders restraining or prohibiting the buyout.
4. GSK has agreed to pay a break fee of $200 million if the buyout doesn't go through. This might happen if one of the three situations arises. One: The GSK Board changes, withdraws or qualifies its recommendation. Two: GSK shareholders vote on the buyout and do not approve it. Three: no vote is held on the buyout by August 31, 2018.
5. Completion of the buyout is currently expected to occur during the summer of 2018. A circular setting out details that include the resolution seeking shareholder approval will be sent to GSK shareholders.
6. In order to aid the buyout, GSK might sell Horlicks and other consumer nutritional products, it said in its statement. The company further stated that it might also consider the sale of its Indian subsidiary, GlaxoSmithKline Consumer Healthcare.
7. The buyout by GSK of Novartis stake removes this uncertainty for the Consumer Durables, and improves the Group's ability to plan allocation of capital to its other priorities.Â
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business. Press release: https://t.co/CuJcTFc77N pic.twitter.com/w2d8dsLemn— GSK (@GSK) March 27, 2018
8. "The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world's leading Consumer Healthcare businesses. Most importantly it also removes uncertainty and allows us to plan use of our capital for other priorities, especially pharmaceuticals R&D,"Â GSK chief executive officer of Emma Walmsley said.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
